Olema Pharmaceuticals Files 8-K

Ticker: OLMA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1750284

Olema Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyOlema Pharmaceuticals, INC. (OLMA)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC Filing, Regulation FD

TL;DR

Olema Pharma filed a routine 8-K, no major news.

AI Summary

Olema Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Olema Pharmaceuticals is meeting its regular reporting obligations with the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for regulatory and exhibit purposes, not indicating any specific new risks or material events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Olema Pharmaceuticals?

The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated by the 'ITEM INFORMATION' section.

On what date was the earliest event reported in this filing?

The earliest event reported was on January 13, 2025.

In which U.S. state is Olema Pharmaceuticals incorporated?

Olema Pharmaceuticals, Inc. is incorporated in Delaware.

What is the principal executive office address for Olema Pharmaceuticals?

The principal executive offices are located at 780 Brannan Street, San Francisco, California, 94103.

Does this filing announce any specific new material events or financial results?

Based on the provided text, this filing primarily serves as a notification for Regulation FD Disclosure and the submission of exhibits and financial statements, without detailing specific new material events or financial results.

Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-13 07:15:14

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Olema Pharmaceuticals, Inc. (the "Company") made available on its website a copy of the Company's presentation to be shared with investors and others from time to time. The presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated January 13, 2025, of Olema Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OLEMA PHARMACEUTICALS, INC. Date: January 13, 2025 By: /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing